Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04141644 · ClinicalTrials.gov registry record · Phase 1
Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC
A Phase 1 study of Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder), sponsored by University of Utah.
- Active
- Registry status
- Phase 1
- Development phase
- 24
- Enrollment target
- 1
- Study location
NCT04141644 is a Phase 1 study of Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) that is active but no longer recruiting, run by University of Utah. The registered enrollment target is 24 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04141644, a Phase 1 study of Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder), is active but no longer recruiting, sponsored by University of Utah.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 24 participants
- Enrollment target
- 1
- Study location
Study Summary
This is a prospective, open label, interventional trial beginning with a phase 1b safety run-in followed by an expansion cohort.
Conditions Studied
Interventions
- DRUG Osimertinib
- DRUG Ipilimumab
Study Locations (1)
Utah
- Huntsman Cancer Institute - Salt Lake City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 24 participants |
| Start Date | 2020-08-20 |
| Est. Completion | 2028-04-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04141644
The ClinicalTrials.gov registry entry for NCT04141644 describes a study currently listed as active not recruiting, categorized as Phase 1. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Utah, which has 818 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder) appearing as the primary indexed condition, and to 2 interventions - of which Osimertinib is the first listed.
NCT04141644 reports 1 study location spanning 1 distinct geographic area - top geographies include Utah.
Frequently Asked Questions
What is clinical trial NCT04141644 about?
NCT04141644 is a clinical study titled "Safety and Efficacy of Combination Osimertinib and Ipilimumab in Patients w EGFR Mutated NSCLC". This is a prospective, open label, interventional trial beginning with a phase 1b safety run-in followed by an expansion cohort.
What is the current status of trial NCT04141644?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 24 participants. The study started on 2020-08-20. Estimated completion is 2028-04-30.
What conditions does trial NCT04141644 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor (Disorder).
What interventions are being tested in trial NCT04141644?
The interventions under investigation include: Osimertinib (DRUG), Ipilimumab (DRUG).
Who is sponsoring clinical trial NCT04141644?
This trial is sponsored by University of Utah, which has 818 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04141644 being conducted?
This trial has 1 study location across Utah. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.